Man with hands crossed looking into camera. “Your patients may be saying, ‘It’s time to treat my TD’” written next to him

“It’s Not OK, It’s Time to Treat TD”

Patients may come to you to ask whether the involuntary movements they are experiencing may be tardive dyskinesia (TD).

Below, you can find resources to help patients learn more about TD symptom control with AUSTEDO.1

AAN, American Academy of Neurology; APA, American Psychiatric Association. 

As patients reach out, be well-prepared to talk about AUSTEDO

REFERENCES: 1. AUSTEDO® (deutetrabenazine) tablets current Prescribing Information. Parsippany, NJ, Teva Neuroscience, Inc. 2. Fernandez HH, Stamler D, Davis MD, et al. Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. J Neurol Neurosurg Psychiatry. 2019;90(12):1317-1323. 3. Data on file. Parsippany, NJ: Teva Neuroscience, Inc.